Ocala Royal Dames for Cancer Research (ORD) Grants

The Ocala Royal Dames for Cancer Research, Inc. offers two-year funding support of $50,000 to be paid at $25,000 per year for medical research into finding cures for cancer. We are looking for research that can be described as translational, preclinical — NOT early bench work. It should be aimed specifically at cancer and have a potential of usefulness in the near future. We do not wish to fund a study that is supported by drug companies. We expect to receive recognition in any resulting publication of the work. Monies awarded may be applied to direct research costs only, which may include salary support for technical personnel working directly on the project. The grant is not intended to reimburse principal investigator salary. Research may be laboratory based or clinical (diagnostic or therapeutic.)

UF may submit seven applications in response to this solicitation. Interested applicants should submit an internal Letter of Intent to the UFHCC Research Administration team (ResearchAdmin@cancer.ufl.edu) by Jan. 15, 2018 for internal coordination.

NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)

The objective of this award is to identify and encourage outstanding graduate students who are recognized by their institutions as having high potential and strong interest in pursuing careers as independent cancer researchers, and then to facilitate their successful transition to postdoctoral positions. The F99/K00 award is intended for individuals who require one to two years to complete their Ph.D. dissertation research training (F99 phase) before transitioning to mentored postdoctoral research training (K00 phase). Consequently, applicants are expected to propose an individualized research training plan for the next one to two years of dissertation research training and a plan for three to four years of mentored postdoctoral research and career development activities that will prepare them for independent cancer-focused research careers.

UF may submit only one application for this RFA. Interested applicants should submit an internal Letter of Intent to the UFHCC Research Administration team (ResearchAdmin@cancer.ufl.edu) by Jan. 8, 2018 for internal coordination.

The following is a list of new cancer-focused extramural funding opportunities. To stay updated throughout the month, please visit our website.

National Institutes of Health

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

LOI due date: 1/28/18  Application due date: 2/28/18

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

LOI due date: 1/28/18  Application due date: 2/28/18

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)

LOI due date: 1/28/18  Application due date: 2/28/18

Mentored Clinical Scientist Research Career Development Award (Parent K08 – Independent Clinical Trial Not Allowed)

Application due date: 2/12/18

Methodology and Measurement in the Behavioral and Social Sciences (R01 Clinical Trial Optional)

Application due date: 2/5/18

Methodology and Measurement in the Behavioral and Social Sciences (R21 Clinical Trial Optional)

Application due date: 2/16/18

NCI Clinical and Translational Exploratory/Developmental Studies  (R21 Clinical Trial Optional)

Application due date: 2/20/18

NCI Mentored Research Scientist Development Award to Promote Diversity (K01 – Clinical Trial Required)

Application due date: 2/12/18

NCI Mentored Research Scientist Development Award to Promote Diversity (K01 -Independent Clinical Trial Not Allowed)

Application due date: 2/12/18

NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional)

Application due date: 2/28/18

NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)

Application due date: 2/12/18

NCI Transition Career Development Award to Promote Diversity (K22 No Independent Clinical Trials)

Application due date: 2/12/18

Population Health Interventions: Integrating Individual and Group Level Evidence (R21) –Clinical Trial Not Allowed

Application due date: 2/12/18

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)

Application due date: 1/25/18

Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R21/R33 Clinical Trial Optional)

LOI due date: 1/17/18  Application due date: 2/16/18

Tobacco Regulatory Science (R01  Clinical Trial Optional) (R21  Clinical Trial Optional)

LOI due date: 12/13/17   Application due date: 2/13/18

Tobacco Regulatory Science Small Grant Program for New Investigators (R03  Clinical Trial Optional)

LOI due date: 12/13/17   Application due date: 2/13/18

Education and Health: New Frontiers (R01) Clinical Trial Optional

Application due date: 2/5/18

Education and Health: New Frontiers (R21) Clinical Trial Optional (R03) Clinical Trial Optional

Application due date: 2/16/18

Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional) (R21 Clinical Trial Optional)

LOI due date: 3/11/18  Application due date: 4/11/18

Predicting Behavioral Responses to Population-Level Cancer Control Strategies (R21 Clinical Trial Optional)

LOI due date: 3/11/18  Application due date: 4/11/18

Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01 Clinical Trial Optional)

LOI due date: 4/9/18  Application due date: 5/9/18

Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3 Clinical Trial Optional)

LOI due date: 4/9/18  Application due date: 5/9/18